Virology News and Research

Latest Virology News and Research

CD8+T cells may aid in developing AIDS vaccine: New Journal of Physics

Limited success in modelling the behaviour of the complex, unusual and unpredictable HIV virus has slowed efforts to develop an effective vaccine to prevent AIDS.

29 Apr 2010

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

29 Apr 2010

Scientists discover human DNA that act as a traitor to body's defences

Cancer Research UK-funded scientists have discovered that stretches of human DNA act as a traitor to the body's defences by helping viruses infect people and trigger cancer-causing diseases, according to a study published in Nature Cell Biology today.

28 Apr 2010

Stalk structure of Mx protein restrains components of influenza virus in infected cells

When the human body becomes infected with new influenza viruses, the immune system rapidly activates an inborn protective mechanism to inhibit the intruding pathogen. A protein known as Mx plays an important role in this process, keeping the spread of viruses in check. Exactly how Mx accomplishes this task was previously unknown.

28 Apr 2010

FDHN announces 2010 AGA Research Scholars

The Foundation for Digestive Health and Nutrition has announced the 2010 American Gastroenterological Association Foundation research scholars. The grants have been awarded to seven outstanding young gastroenterologists who promise to make significant strides in the field of gastrointestinal research.

28 Apr 2010

Study evaluates cost benefits of new interventions for treating, preventing PDN and PHN

Constantly rising U.S. health care costs could be reduced significantly by preventing and treating neuropathic pain conditions associated with diabetes and herpes zoster virus infections, according to research published in The Journal of Pain, the peer review publication of the American Pain Society, www.ampainsoc.org and jpain.org.

28 Apr 2010

ChronSeal multi-center study in Sweden and Norway finalized

The multi-center study in Sweden and Norway with ChronSeal® is now finalized and the data are being analyzed in Sweden and by Kringle in Japan. ChronTech and Kringle have jointly decided that the results will be publicly available on May 27th. At follow-up of the ChronVac-C® -study where patients now have started treatment according to standard-of-care (interferon and ribavirin) all patients (100%) were virus free at treatment week 12 and 5/6 (83%) had less than 50 copies of virus/mL blood already at treatment week four.

28 Apr 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

International initiative seeks to reduce heterosexual HIV transmission

Los Angeles Biomedical Research Institute has received a $350,000 grant to study the safety of a gel designed to reduce the heterosexual transmission of HIV from the International Partnership for Microbicides, a nonprofit global initiative to develop products to reduce HIV transmission, and the U.S. Agency for International Development, the Institute announced today.

28 Apr 2010

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.

27 Apr 2010

WHO experts to examine polio outbreak in Tajikistan

The WHO said it sent six technical experts to assess a small outbreak of polio in Tajikistan, VOA News reports, adding that WHO "says this is the first importation of polio in the European region since Europe was certified as polio-free in 2002."

27 Apr 2010

Wall Street Journal examines changes to polio eradication strategy

The Wall Street Journal examines upcoming changes to the global strategy to eradicate polio with a focus on the Bill & Melinda Gates Foundation's role in fighting the disease. "[O]rganizations behind the polio fight," which include the WHO, UNICEF, Rotary International and the CDC, "plan to announce a major revamp of their strategy to address shortcomings exposed by" the increasing number of polio outbreaks in "countries believed to have stopped the disease." The plan is expected to be announced next week.

27 Apr 2010

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

Scientists at Australia's Burnet Institute have developed a rapid point-of-care diagnostic test for the measurement of CD4 T-cells, a marker of the immune system for people living with HIV and AIDS.

27 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Pevion Biotech, the Swiss vaccine company, today announced that it has successfully completed the preclinical safety and efficacy studies of its RSV vaccine candidate PEV4. The vaccine candidate is a modern subunit vaccine candidate against respiratory syncytial virus (RSV), which is based on a recombinant RSV-F protein formulated with Pevion Biotech's proprietary and market-validated virosome technology platform.

26 Apr 2010

Study finds changes in astrocytes key to brain dysfunction

Neuroscience researchers have zeroed in on a novel mechanism that helps control the firing of electrical signals among neurons. By isolating the molecular and electrical events that occur when this control is disrupted, the new research sheds light on epileptic seizures and potentially on other prominent diseases involving poorly regulated brain activity.

26 Apr 2010

1976 "swine flu" vaccine protects against 2009 pandemic H1N1 influenza virus

New evidence shows immunization against "swine flu" in 1976 might provide individuals with some protection against the 2009 pandemic H1N1 influenza virus, according to new research from St. Jude investigators.

24 Apr 2010

Mechanisms pathogenic viruses exploit to evade immune systems of hosts

Viruses have evolved a broad range of strategies that enable them to evade the immune systems of their hosts. A team of researchers led by LMU virologist Professor J-rgen Haas has been studying a novel, recently discovered mechanism that pathogenic viruses exploit for this purpose, and their latest results could point the way to new antiviral therapies. The mechanism is based on the production of short RNA molecules, called microRNAs, by the virus.

24 Apr 2010

Presidio Pharmaceuticals, Numerate conclude collaboration to discover new compounds targeting HCV

Presidio Pharmaceuticals, Inc., and Numerate, Inc., today announced that they have concluded their two-year collaboration to discover new compounds that target hepatitis C virus (HCV).

24 Apr 2010

Virology News and Research

Latest Virology News and Research

CD8+T cells may aid in developing AIDS vaccine: New Journal of Physics

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Scientists discover human DNA that act as a traitor to body's defences

Stalk structure of Mx protein restrains components of influenza virus in infected cells

FDHN announces 2010 AGA Research Scholars

Study evaluates cost benefits of new interventions for treating, preventing PDN and PHN

ChronSeal multi-center study in Sweden and Norway finalized

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

International initiative seeks to reduce heterosexual HIV transmission

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

WHO experts to examine polio outbreak in Tajikistan

Wall Street Journal examines changes to polio eradication strategy

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Nanoviricides become registered trademark under USPTO

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Study finds changes in astrocytes key to brain dysfunction

1976 "swine flu" vaccine protects against 2009 pandemic H1N1 influenza virus

Mechanisms pathogenic viruses exploit to evade immune systems of hosts

Presidio Pharmaceuticals, Numerate conclude collaboration to discover new compounds targeting HCV

Microplate-based assays in virology research eBook eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting